Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.

Journal of Crohn's & colitis·2026

Same author

Third N-ECCO Consensus Statements on the Nursing Roles in Caring for Patients with Inflammatory Bowel Disease.

Journal of Crohn's & colitis·2026

Same author

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment.

Journal of Crohn's & colitis·2026

Same author

[Acute appendicitis : can surgery be avoided ?]

Revue medicale suisse·2026

Same author

Population-Based Assessment of Phenoconversion Potential in Switzerland: A Claims Data Study of Key Drug-Metabolizing Enzymes and Transporters.

Pharmacogenomics and personalized medicine·2026

Same author

The Role of the Mesopancreas in Periampullary Malignancies.

Cancers·2026

Search research articles

Related Experiment Video

Updated: Jan 8, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

IL-6/GP130/JAK/STAT3 Pathway Activation in Pancreatic Ductal Adenocarcinoma and Its Association With Clinical

Claudia Mellenthin^1,2, Fabien Schaller^1,2, Lucie Vignot³

¹Department of Surgery, Hospital Fribourg, Fribourg, Switzerland.

JMIR Research Protocols

|December 15, 2025

Summary

This summary is machine-generated.

The interleukin 6 (IL-6)/glycoprotein 130 (GP130)/Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) pathway is activated in pancreatic cancer. This study links pathway activation to clinical outcomes, informing targeted therapies.

Keywords:

IL-6 STAT3 inflammation interleukin 6 pancreatic cancer signal transducer and activator of transcription 3 survival

More Related Videos

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

Related Experiment Videos

Last Updated: Jan 8, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

Area of Science:

Oncology
Molecular Biology
Translational Research

Background:

The proinflammatory cytokine interleukin 6 (IL-6) drives pancreatic cancer by activating the Janus kinase (JAK)-signal transducer and activator of transcription 3 (STAT3) pathway.
Targeting the IL-6/glycoprotein 130 (GP130)/JAK/STAT3 axis presents a potential therapeutic strategy for pancreatic adenocarcinoma.

Purpose of the Study:

Investigate IL-6/GP130/JAK/STAT3 pathway activation in pancreatic adenocarcinoma.
Quantify pathway expression in tumor and stromal compartments.
Explore associations between pathway activation and clinical outcomes, including survival and metabolic parameters like diabetes.

Main Methods:

Retrospective analysis of archived pancreatic adenocarcinoma biopsy samples.
Immunostaining for phospho-STAT3 to assess GP130 receptor activation.
Quantification of stained cells using QPath software and statistical analysis of clinical and metabolic data.

Main Results:

150 patient records identified; screening ongoing.
Study is ongoing, with sample size calculations based on expected poorer prognoses in patients with higher pathway activation.

Conclusions:

This study is a pioneering translational investigation of the IL-6/GP130/JAK/STAT3 pathway in pancreatic adenocarcinoma.
Correlating molecular pathway activation with clinical and metabolic features will offer insights into disease heterogeneity.
Findings will support the development of personalized, pathway-targeted therapeutic strategies for pancreatic cancer.